Regorafenib treatment for advanced, refractory gastrointestinal stromal tumor: a report of the UK managed access program

BACKGROUND: Tyrosine kinase inhibitors (TKI) have revolutionized the treatment of gastrointestinal stromal tumors (GIST) although most patients develop resistance to first and second-line therapies. Regorafenib, an oral multi-targeted TKI, has demonstrated benefit in previously treated GIST patients...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Sarcoma Res
Asıl Yazarlar: Kollàr, Attila, Maruzzo, Marco, Messiou, Christina, Cartwright, Elisabeth, Miah, Aisha, Martin-Liberal, Juan, Thway, Khin, McGrath, Ellen, Dunlop, Alison, Khabra, Komel, Seddon, Beatrice, Dileo, Palma, Linch, Mark, Judson, Ian, Benson, Charlotte
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2014
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4405914/
https://ncbi.nlm.nih.gov/pubmed/25905001
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/2045-3329-4-17
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller